WebPRDS: Get the latest Pardes Biosciences stock price and detailed information including PRDS news, historical charts and realtime prices. WebApr 12, 2024 · benzinga.com - January 14 at 10:22 PM. Pardes Biosciences, Inc. (NASDAQ:PRDS) Is Expected To Breakeven In The Near Future. finance.yahoo.com - November 13 at 6:59 PM. Pardes Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update. apnews.com - November 8 at 12:02 PM.
Pardes Biosciences - Change. Medicine.
WebFounded. 2024. Pardes Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing and commercializing novel therapeutics to treat … WebMar 15, 2024 · JMP Securities analyst Roy Buchanan reiterated a Buy rating on Pardes Biosciences ( PRDS – Research Report) today and set a price target of $5.00. The company’s shares closed yesterday at $1. ... nipsey roc nation brunch
PRDS Pardes Biosciences Inc. Profile MarketWatch
WebIPO Date. 2024-01-14. Description. Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes ... WebSee Pardes Biosciences, Inc revenue breakdown by source and country: learn where the money comes from to better understand how the company operates WebNov 18, 2024 · In a report released on November 7, Roanna Ruiz from SVB Securities reiterated a Buy rating on Pardes Biosciences (PRDS - Research Report), with a price target of $12.00. The company's shares closed yesterday at $1.19.According to TipRanks, Ruiz is an analyst with an average return of -46.4% and a 12.77% success rate. numbers pinyin